Salix Pharmaceuticals (SLXP) Presents Data on Mesalamine Granules Once-Daily Maintained Remission at ACG 2008

October 7, 2008 8:31 AM EDT Send to a Friend
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that 1.5 g mesalamine granules once-daily maintained remission versus placebo in ulcerative colitis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login